AzurRX acquires First Wave Bio and with it niclosamide.
The combined company will change its name to First Wave BioPharma and start trading on the Nasdaq under its new ticker, “FWBI,” next week. The buyout comes eight months after AzurRx licensed two programs from First Wave based on niclosamide, an oral small molecule drug with antiviral and anti-inflammatory properties. One is in development for COVID-19-related GI infections and colitis and diarrhea stemming from checkpoint inhibitor treatment. Besides these two programs, AzurRx adds several new niclosamide-based treatments for inflammatory bowel disease to its pipeline through the deal. These include programs in ulcerative proctitis, ulcerative proctosigmoiditis, ulcerative colitis and Crohn’s disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins